公开(公告)号：US20020044963A1

公开(公告)日：2002-04-18

申请号：US09737987

申请日：2000-12-15

Inventor： John J. Gaudino

IPC: C07D413/00 ,  C07D201/00 ,  C07D235/04 ,  C07D231/56 ,  A61K009/20

CPC classification number: C07D403/04

Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.

公开(公告)号：US10676458B2

公开(公告)日：2020-06-09

申请号：US16083677

申请日：2017-03-24

Applicant: Merck Sharp & Dohme Corp.

Inventor： Michael Miller ,  Harry R. Chobanian

IPC: C07D215/14 ,  C07D401/04 ,  C07D201/00 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/538 ,  A61K45/06 ,  C07D265/36 ,  C07D413/04

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

公开(公告)号：US09206457B2

公开(公告)日：2015-12-08

申请号：US12952036

申请日：2010-11-22

Applicant: Hung V. Do

Inventor： Hung V. Do

IPC: C12P21/02 ,  C07D201/00 ,  C12N5/07 ,  C12N5/10 ,  C12N9/00 ,  C07K5/00 ,  C07K7/00 ,  C07K16/00 ,  C07K17/00 ,  A61K38/00 ,  C07K1/14 ,  C07K1/22

CPC classification number: C12P21/02 ,  C07D201/00 ,  C07K1/14 ,  C07K1/22 ,  C12Y302/01054

Abstract: The present invention provides methods for improving the production of recombinant proteins through the use of pharmacological chaperones for the recombinant proteins. As exemplified by the present invention, the binding of a pharmacological chaperone to a recombinant protein expressed by a cell can stabilize the protein and increase export of the protein out of the cell's endoplasmic reticulum, and increase secretion of the protein by the cell.

Abstract translation: 本发明提供了通过使用用于重组蛋白的药理学伴侣来改善重组蛋白质生产的方法。 如本发明所示，药物伴侣与由细胞表达的重组蛋白的结合可稳定蛋白质并增加蛋白质从细胞内质网中的输出，并增加细胞分泌蛋白质。

公开(公告)号：US08212027B1

公开(公告)日：2012-07-03

申请号：US13095523

申请日：2011-04-27

Applicant: Lee Keith Woo ,  Robert J. Angelici

Inventor： Lee Keith Woo ,  Robert J. Angelici

IPC: C07D201/00 ,  C07D213/63 ,  C07D207/00

CPC classification number: C07D211/76

Abstract: Converting cyclic amines to lactams using gold supported catalysts.

Abstract translation: 使用金支持的催化剂将环胺转化为内酰胺。

公开(公告)号：US20020006378A1

公开(公告)日：2002-01-17

申请号：US08975090

申请日：1997-11-20

Inventor： STUART W. YOUNG ,  MEREDITH WRIGHT ,  JONATHAN L. SESSLER ,  TARAK D. MODY ,  DARREN MAGDA

IPC: C07F001/00 ,  C07D201/00 ,  A61M036/14 ,  A61K051/00 ,  A61B005/055 ,  C09B047/00 ,  C07D213/00 ,  A61K049/04 ,  A61B010/00

CPC classification number: B82Y5/00 ,  A61K41/0076 ,  A61K47/554 ,  A61K47/6901 ,  A61K47/6911 ,  A61K49/085 ,  A61K49/1896

Abstract: Compositions having a texaphyrin-lipophilic molecule conjugate loaded into a biological vesicle and methods for imaging, diagnosis and treatment using the loaded vesicle are provided. For example, liposomes or red blood cells loaded with a paramagnetic texaphyrin-lipophilic molecule conjugate have utility as a blood pool contrast agent, facilitating the enhancement of normal tissues, magnetic resonance angiography, and marking areas of damaged endothelium by their egress through fenestrations or damaged portions of the blood vascular system. Liposomes or cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate can be photolysed, allowing for a photodynamic therapy effect at the site of lysis. Availability of red blood cells loaded with a photosensitive texaphyrin-lipophilic molecule conjugate provides a method for delivering a photodynamic therapeutic agent to a desired site with a high concentration of oxygen. By presenting the agent in this way, it is expected that a patient will experience less toxicity.

Abstract translation: 提供了具有加载到生物囊泡中的泰克萨菲瑞 - 亲脂性分子缀合物的组合物以及使用加载的囊泡进行成像，诊断和治疗的方法。 例如，装载有顺磁性泰克萨菲瑞 - 亲脂性分子缀合物的脂质体或红细胞具有作为血液池造影剂的效用，有利于正常组织的增强，磁共振血管造影术，以及通过开窗口或损伤引起的出血损伤的内皮标记区域 部分血管系统。 可以光密化具有感光性泰克萨菲瑞 - 亲脂性分子缀合物的脂质体或细胞，从而在裂解部位产生光动力学治疗效果。 载有感光性泰克萨菲瑞 - 亲脂性分子缀合物的红细胞的可获得性提供了一种将光动力治疗剂递送至具有高浓度氧的所需部位的方法。 通过以这种方式呈现代理，预期患者的毒性将较低。

公开(公告)号：US5277772A

公开(公告)日：1994-01-11

申请号：US692083

申请日：1991-04-26

Applicant: Mark A. Harmer

Inventor： Mark A. Harmer

IPC: C03C17/28 ,  C03C23/00 ,  C08F8/30 ,  D06M13/252 ,  D06M13/355 ,  D06M23/00 ,  G01N33/543 ,  G03C1/695 ,  G03F7/012 ,  G03F7/20 ,  C07D201/00

CPC classification number: D06M13/252 ,  C03C17/28 ,  C03C23/0015 ,  C08F8/30 ,  D06M13/355 ,  D06M23/005 ,  G01N33/54353 ,  G03C1/695 ,  G03F7/012 ,  G03F7/2041

Abstract: The invention concerns a method for the chemical modification of a surface based on the reaction of photolytically generated reactive intermediates derived from azido heterocycles with said surface.

Abstract translation: 本发明涉及一种用于基于衍生自叠氮基杂环的光解产生的反应中间体与所述表面的反应来化学修饰表面的方法。

公开(公告)号：US4338262A

公开(公告)日：1982-07-06

申请号：US180275

申请日：1980-08-21

Applicant: Otto Schallner ,  Siegfried Oeckl ,  Karl H. Schundehutte

Inventor： Otto Schallner ,  Siegfried Oeckl ,  Karl H. Schundehutte

IPC: C07C317/44 ,  C07C67/00 ,  C07C313/00 ,  C07C317/00 ,  C07C317/04 ,  C07C317/14 ,  C07D201/00 ,  C07C147/02 ,  C07C147/06

CPC classification number: C07C317/00

Abstract: Acid halides and anhydrides of acids of the formula ##STR1## with the substituent definitions given in the description are obtained by reacting the corresponding acids with organic or inorganic acid halides or acid anhydrides. The new compounds are intermediate products for the preparation of new reactive dyestuffs.

Abstract translation: 通过使相应的酸与有机或无机酰卤或酸酐反应，得到具有本说明书中给出的取代基定义的式“IMAGE”的酸的酰卤和酸酐。 新化合物是用于制备新的活性染料的中间产物。

公开(公告)号：US3991115A

公开(公告)日：1976-11-09

申请号：US633208

申请日：1975-11-19

Applicant: Richard Lynn Purgason

Inventor： Richard Lynn Purgason

IPC: C07D201/04 ,  C07D201/00 ,  C07C131/04

CPC classification number: C07C249/08

Abstract: This invention relates to a process for the production of cyclohexanone oxime by reacting cyclohexanone with excess aqueous hydroxylamine in the presence of excess ammonia. More specifically, the invention relates to improving yields of the oxime while reducing undesirable by-product formation by use of two or more stages of reaction with correlated adjustment of reaction conditions in each stage. The invention also involves improved recovery of the unreacted hydroxylamine reactant for recycle in the process.

Abstract translation: 本发明涉及通过在过量氨的存在下使环己酮与过量的羟胺反应生产环己酮肟的方法。 更具体地说，本发明涉及提高肟的产率，同时通过使用两阶段或更多阶段的反应，同时在每个阶段的反应条件的相关调整来减少不希望的副产物形成。 本发明还涉及在该方法中回收未反应的羟胺反应物以进行再循环。

公开(公告)号：US2960499A

公开(公告)日：1960-11-15

申请号：US76912358

申请日：1958-10-23

Applicant: STAMICARBON

Inventor： BOON JOHANNES W P

IPC: C07D201/00 ,  C07D201/16

CPC classification number: C07D201/16 ,  C07D201/00

公开(公告)号：US11767330B2

公开(公告)日：2023-09-26

申请号：US17858875

申请日：2022-07-06

Applicant: Foghorn Therapeutics Inc.

Inventor： Chong-Hui Gu ,  Joshua D. Waetzig

IPC: C07D519/00 ,  C07D201/00 ,  A61K31/4545

CPC classification number: C07D519/00 ,  C07B2200/13

Abstract: The present disclosure features citrate salts and pharmaceutical compositions useful for the treatment of BAF complex-related disorders. Also disclosed are methods for preparing compounds.